The programme spans multiple trials targeting distinct endpoints: On 21 May 2026 Eli Lilly reported topline results from TRIUMPH-1, the pivotal Phase 3 obesity trial and the programme's first Phase 3 efficacy readout: in 2,339 adults, mean weight loss at the 80-week primary endpoint reached 19.0% (4mg), 25.9% (9mg), and 28.3% (12mg) versus 2.2% for placebo (Eli Lilly investor release
Not a stimulant just better hormonal balance
Many customers incorporate them throughout the day, pairing protein powder & non-dairy colostrum in the morning, bone broth midday, and hydration as needed
But I always advise patients to resist the temptation to cut their calories too much too soon
Common side effects Nausea Diarrhea or constipation Vomiting Abdominal pain Fatigue Serious risks Pancreatitis (inflammation of the pancreas) Gallbladder problems Low blood sugar, especially with other diabetes medicines Kidney problems related to dehydration Serious allergic reactions Do not use if you have Personal or family history of medullary thyroid carcinoma Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) Known serious allergy to semaglutide Pregnancy or breastfeeding Frequently asked questions What is microdosing